The AJMC® Precision Medicine in Oncology compendium is a comprehensive resource for clinical news and expert insights for molecular profiling of tumors.
Review Determines Cost-effectiveness of Precision Diagnostic Testing in NSCLC
August 7th 2021The analysis included 64 cost-effectiveness analysis scenarios across more than 30 studies between 2009 and 2019, approximately half (53%) of which determined precision diagnostic testing to be cost-effective.
Read More
Monitoring MRD Can Help Diagnose Cutaneous T-Cell Lymphoma
August 5th 2021Researchers were able to use a next-generation sequencing assay to not only monitor minimal residual disease (MRD), but also to confirm diagnosis of cutaneous T-cell lymphoma, which can present as more benign conditions early on.
Read More
Number of Plasma Variants Associated With Lung Cancer Survival, Says Liquid Biopsy Analysis
July 18th 2021Researchers have found that the number of variants a patient had in their plasma had prognosis implications, with circulating cell-free DNA mutational load having a significant association with overall survival.
Read More
Genomics-Informed Treatment Prolongs Time to Treatment Discontinuation, Study Says
July 13th 2021Based on difference-in-difference (DID) analysis, genomics-informed treatment increased time to treatment discontinuation by an estimated 3 months and increased costs by an estimated C$90,000—equivalent to approximately US$72,000—compared with standard care treatment.
Read More
Presence of Postoperative ctDNA May Be Predictive of Recurrence Risk in Colorectal Cancer
June 26th 2021Based on the prognostic value observed in the study, the researchers suggest that evaluating circulating tumor DNA (ctDNA) status as early as within a week of surgery could aid in risk stratification of patients and decision-making for postoperative management.
Read More
Identifying Surrogate End Points for PFS in Newly Diagnosed Multiple Myeloma
June 25th 2021Minimal residual disease, overall response rate, complete response rate, and stringent complete response may be useful as surrogate end points to estimate progression-free survival (PFS) benefit for patients with newly diagnosed multiple myeloma.
Read More
Study Finds Genomics, Precision Medicine May Exacerbate Racial Disparities in Prostate Cancer
June 19th 2021New research presented at the 2021 American Society of Clinical Oncology Annual Meeting is painting a clearer picture of what drives differences in mortality and outcomes for patients with prostate cancer. Black men with prostate cancer have higher incidence of both.
Read More
“Unfavorable Genetics” Negatively Impacted MRD in Some Patients With R/R CLL
June 17th 2021Favorable genetic characteristics may be able to predict which patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who were treated with venetoclax-rituximab will attain undetectable minimal residual disease (MRD).
Read More
Mutation Prevalence in mCRC May Differ Based on Certain Patient Characteristics
May 13th 2021Using biomarkers to guide treatment decisions are increasingly being leveraged across various cancers, and metastatic colorectal cancer (mCRC) is no exception. However, the positivity rates of these biomarkers can differ across different patient characteristics, according to a recent study.
Read More
AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews. These interviews have been edited lightly for clarity.
Read More